PLURI
Pluri is at the forefront of a biotech revolution that promotes global well-being and sustainability by developing marketable cell-based solutions.
PLURI
Industry:
3D Technology Biotechnology Therapeutics
Founded:
2003-01-01
Address:
Haifa, Hefa, Israel
Country:
Israel
Website Url:
http://www.pluristem.com
Total Employee:
101+
Status:
Active
Contact:
972-74-7108600
Email Addresses:
[email protected]
Total Funding:
162.5 M USD
Technology used in webpage:
Domain Not Resolving Gravity Forms Microsoft Power BI 012 Smile Your Mailing List Provider PandaDoc
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Allevi
Allevi offers bioprinters that enable users to experiment with any biomaterial, work with any cell line, and print in any geometry.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Interius BioTherapeutics
Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - Pluri
Innovative Medical Management
Innovative Medical Management investment in Post-IPO Equity - Pluri
Office of the Chief Scientist
Office of the Chief Scientist investment in Grant - Pluri
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-06-18 | Ever After Foods | Pluri investment in Venture Round - Ever After Foods | 10 M USD |
Official Site Inspections
http://www.pluristem.com
- Host name: pluri-biotech1.tempurl.host
- IP address: 107.191.40.71
- Location: Piscataway United States
- Latitude: 40.5511
- Longitude: -74.4606
- Metro Code: 501
- Timezone: America/New_York
- Postal: 08854
More informations about "Pluri"
Pluri - Crunchbase Company Profile & Funding
Sub-Organization of . Yeda Research and Development Co. Ltd . Founded Date 2003; Founders Shai Meretzki; ... Also Known As Pluristem Therapeutics; Legal Name Pluri™ Inc; Stock …See details»
Pluri Inc. - Wikipedia
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas. See details»
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” …
HAIFA, Israel, July 25, 2022 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced its name change (from …See details»
Pluristem Therapeutics Inc. Changes its Name to “Pluri
As of July 26, 2022, Pluri’s stock will trade under the symbol PLUR; The new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields ...See details»
Pluristem Therapeutics - Overview, News & Similar companies
Jul 25, 2022 Who is Pluristem Therapeutics. Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture …See details»
Pluristem Therapeutics Inc. - Devex
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for ...See details»
Pluristem Therapeutics, Inc. - AnnualReports.com
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented …See details»
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” …
Jul 25, 2022 Pluri Inc. logo WHERE TECHNOLOGY COMES TO LIFE As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy …See details»
Pluristem to Receive €20M Non-Dilutive Funding from the …
May 25, 2021 Pluristem’s key competitive advantages include a state-of-the-art, automated cell expansion technology that draws on 17 years of cell therapy research.See details»
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading …See details»
Pluristem | Drug Discovery News
Oct 8, 2013 by Dr. Malki Epel and Pluristem A guide for potency assay development of cell-based product candidates The development of a potency assay for cellular therapy products …See details»
Pluristem Releases PLX-R18 Hematology Phase I Study
Mar 23, 2022 Pluristem is pushing the boundaries of science and engineering to produce cell-based products for various industries on a global scale. The Company’s cell manufacturing …See details»
Thermo Fisher, Pluristem partner to scale up ... - Fierce Biotech
Jul 9, 2018 Placenta-based cell therapy company Pluristem Therapeutics has launched a collaboration with Thermo Fisher Scientific to help scale up the manufacturing of regenerative …See details»
Pluristem Therapeutics Inc. Changes its Name to Pluri Inc.-FINAL …
Biotechnology company, today announced its name change (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to …See details»
Israel's Pluristem FDA approved for study in treatment of severe …
May 9, 2020 Israel’s Pluristem Therapeutics’ PLX cells therapy has been cleared by the US Food and Drug Administration for a Phase II study in the treatment of severe COVID-19 cases …See details»
Home Page - pluri-biotech.com
Dec 26, 2022 Accessibility. Accessibility Statement. Pluri Biotech Ltd. is committed to making its electronic and information technologies accessible to individuals with disabilities by meeting or …See details»
Industry Updates from the Field of Stem Cell Research and …
Collaboration agreement: Pluristem & NASA. Pluristem Therapeutics (Israel; www.pluristem.com) has collaborating with the NASA’s Ames Research Center to evaluate the potential of …See details»
Pluristem Reports Topline Results from its Phase II Studies of …
Dec 27, 2021 In July 2021, Pluristem announced its decision to bring the Studies to early clinical readout based on 89 patients enrolled, instead of the originally planned 180 patients (140 in …See details»
Pluristem reports positive topline Phase I results in - GlobeNewswire
Apr 29, 2021 Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported …See details»
Pluristem Receives Approval for Grant from the Israel Innovation ...
Following achievements met in the project, the IIA to provide an additional budget to advance work of CRISPR-IL National Consortium, in which Pluristem is leading the Pharma group, and …See details»